The pharmaceutical industry is set to receive a new boost; thanks to Abattis Bioceuticals Corp (OTCMKTS:ATTBF). The cannabis company well – known for its diversification says it is on the verge of releasing a new chronic pain and inflammation product. The launch of the product known as “Comfort” is as a result of an extensive research by the Cannabis solution provider.
Abattis has been holding onto this vision of enlarging its product line in an effort to propel its vision. This is the more reason it has invested heavily in research, partnerships and comparison studies. It is already working on a phase 1 study, targeting the exploration and the development of nanoemulsified and liposomal platforms. The study is in partnership with the University of British Columbia and Mitacs.
Comfort will address the needs of the severe disabling condition
Chronic pain and inflammation is a growing problem. Reports from the Industry of Medicine indicate that close to 100 million people in North America are at the mercy of this condition. The condition affects the internal systems of a person, which in return fail to produce the required endogenous chemicals. What follows is severe pain known to last for too long.
The report further explains how millions of people are not able to access the necessary medical treatments. They are either too expensive or are not available. This not only brings along lost productivity but in the very severe cases have resulted in death.
However, Abattis President and CEO, Rob Abenante cited, “With Comfort, we hope to address a severely disabling condition that affects a large proportion of our population.”
Abattis is confident about its Research and Development strategy
Apart from partnering with a number of corporations, Abattis is also seeking to obtain a Health Canada dealer’s license. If approved, the company will be able to trade in Cannabis flower and oils. It will also integrate into its business key acquisitions. The company is seriously engaged in growing of its retail distribution. It will leave nothing to chance when it comes to research and development.
Clearly, Abattis is establishing a footprint in the cannabis industry from its research and development work.